Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues

Journal of the National Cancer Institute

Volumn 104, Issue 23, 2012, Pages 1815-1824

  Neumeister, Veronique M ^a   Anagnostou, Valsamo ^a   Siddiqui, Summar ^a   England, Allison Michal ^a   Zarrella, Elizabeth R ^a   Vassilakopoulou, Maria ^a   Parisi, Fabio ^a   Kluger, Yuval ^a   Hicks, David G ^b   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A KINASE ANCHOR PROTEIN 13; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; LYSINE; PROGESTERONE RECEPTOR; TUMOR ANTIGEN; TUMOR MARKER; TYROSINE; UNCLASSIFIED DRUG;

ANTIGENICITY; ARTICLE; BOOTSTRAPPING; BREAST CANCER; CANCER TISSUE; CLINICAL PROTOCOL; COLD ISCHEMIA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ASSAY; TEMPERATURE SENSITIVITY; TISSUE FIXATION; TISSUE MICROARRAY; TISSUE SECTION;

A KINASE ANCHOR PROTEINS; BIOPSY, LARGE-CORE NEEDLE; BREAST NEOPLASMS; COLD ISCHEMIA; CONFOUNDING FACTORS (EPIDEMIOLOGY); FALSE NEGATIVE REACTIONS; FEMALE; FIXATIVES; FLUORESCENT ANTIBODY TECHNIQUE; FORMALDEHYDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KI-67 ANTIGEN; MASTECTOMY, SEGMENTAL; MATCHED-PAIR ANALYSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RESEARCH DESIGN; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870873727     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs438     Document Type: Article

References (37)

1. Dowsett M. Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res. 2003;9(1, pt 2):502S-510S.
2. Caldarella A, et al Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. Pathol Oncol Res. 2011;17(3): 753-758.
3. Kim EK, et al Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study. World J Surg. 2011;35(6):1244-1253.
4. Lips EH, et al Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat. 2012;131(3):827-836.
5. Shao MM, Liu J, Vong J.S., et al A subset of breast cancer predisposes to brain metastasis. Med Mol Morphol. 2011;44(1):15-20.
6. Moon Y.W., Park S, Sohn J.H., et al Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol. 2011;137(7):1123-1130.
7. Anderson H, et al Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer. Ann Oncol. 2011;22(8):1770-1776.
8. Tanei T, Shimomura A, Shimazu K., et al Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol. 2011;37(2):155-161.
9. Moore HM, Compton CC, Alper J, Vaught JB International approaches to advancing biospecimen science. Cancer Epidemiol Biomarkers Prev. 2011;20(5):729-732.
10. Pinhel IF, Macneill FA, Hills M.J., et al Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res. 2010;12(5):R76.
11. Betsou F, Barnes R, Burke T., et al; International Society for Biological and Environmental Repositories (ISBER) Working Group on Biospecimen Science. Human biospecimen research: experimental protocol and quality control tools. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1017-1025.
12. De Cecco L., Musella V, Veneroni S., et al Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer. 2009;9:409.
13. Lim MD, Dickherber A, Compton CC Before you analyze a human specimen, think quality, variability, and bias. Anal Chem. 2011;83(1):8-13.
14. Hammond ME, Hayes DF, Dowsett M, et al; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48-e72.
15. Juhl H. Preanalytical aspects: a neglected issue. Scand J Clin Lab Invest Suppl. 2010;242:63-65.
16. Spruessel A, Steimann G, Jung M., et al Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. BioTechniques. 2004;36(6):1030-1037.
17. Hatzis C, Sun H, Yao H., et al Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J Natl Cancer Inst. 2011;103(24):1871-1883.
18. Yaziji H, Taylor CR, Goldstein N.S., et al; Members of the Standardization Ad-Hoc Consensus Committee. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol. 2008;16(6):513-520.
19. Carlson RW, Allred DC, Anderson B.O., et al; NCCN Breast Cancer Clinical Practice Guidelines Panel. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009;7(2):122-192.
20. Wolff AC, Hammond ME, Schwartz J.N., et al; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-145.
21. Khoury T, Sait S, Hwang H., et al Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009;22(11):1457-1467.
22. Mueller C, Edmiston KH, Carpenter C, et al One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS ONE. 2011;6(8):e23780.
23. Apple S, Pucci R, Lowe A.C., Shintaku I., Shapourifar-Tehrani S, Moatamed N. The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma. Am J Clin Pathol. 2011;135(4):592-598.
24. Baker A.F., Dragovich T, Ihle N.T., Williams R., Fenoglio-Preiser C, Powis G. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res. 2005;11(12):4338-4340.
25. Camp RL, Chung GG, Rimm DL Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8(11):1323-1327.
26. Bordeaux J, Welsh A, Agarwal S., et al Antibody validation. BioTechniques. 2010;48(3):197-209.
27. Espina V, Edmiston KH, Heiby M, et al A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics. 2008;7(10):1998-2018.
28. Araujo RP, Liotta LA, Petricoin EF Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov. 2007;6(11):871-880.
29. Petricoin EF III, Bichsel VE, Calvert VS, et al. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol. 2005;23(15):3614-3621.
30. Bai Y, Tolles J, Cheng H., et al Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Lab Invest. 2011;91(8):1253-1261.
31. Davis BW, Zava DT, Locher G.W., Goldhirsch A., Hartmann WH Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. Eur J Cancer Clin Oncol. 1984;20(3):375-382.
32. Douglas-Jones A.G., Collett N, Morgan J.M., Jasani B. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J Clin Pathol. 2001;54(12):951-955.
33. Sapino A, Marchiò C, Senetta R, et al. Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch. 2006;449(3):288-296.
34. Chung GG, Zerkowski MP, Ghosh S, Camp R.L., Rimm DL Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest. 2007;87(7):662-669.
35. Tolles J, Bai Y, Baquero M., Harris LN, Rimm DL, Molinaro AM Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma. Breast Cancer Res. 2011;13(3):R51.
36. Nassar A, Radhakrishnan A, Cabrero I.A., Cotsonis GA, Cohen C. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Appl Immunohistochem Mol Morphol. 2010;18(5):433-441.
37. Yildiz-Aktas I.Z., Dabbs DJ, Bhargava R. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol. 2012;25(8):1098-1105.